Zoetis Demonstrates Canine Innovation Leadership With Commercial Launch Of Librela; Zoetis Also Launches Apoquel Chewable For The Control Of Pruritus Associated With Allergic Dermatitis And Control Of Atopic Dermatitis In Dogs In The U.S.
Portfolio Pulse from Benzinga Newsdesk
Zoetis has announced the U.S. commercial launch of Librela, an anti-NGF monoclonal antibody treatment for canine osteoarthritis pain, and Apoquel Chewable, a treatment for pruritus associated with allergic dermatitis and atopic dermatitis in dogs. Both products are firsts in their respective categories and aim to improve treatment compliance and quality of life for dogs.
October 09, 2023 | 4:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Zoetis' launch of Librela and Apoquel Chewable could potentially boost its revenues as these products are firsts in their respective categories and address prevalent conditions in dogs.
Zoetis' launch of Librela and Apoquel Chewable, both firsts in their respective categories, could potentially boost its revenues. These products address prevalent conditions in dogs, which could lead to high demand. The company's commitment to canine health and innovation could also strengthen its market position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100